Investigator-initiated trial |
Phase I Single-Administration Study of TRG035 in Healthy Adults |
Department of Early Clinical Development |
Corporate-sponsored trial |
Phase 2 Study of BB-1701 in HER2 positive or HER2-low metastatic breast cancer |
Department of Breast Surgery |
Corporate-sponsored trial |
[M24-742]First-in-Human Study of ABBV-969 in Metastatic Castration-Resistant Prostate Cancer |
Department of Early Clinical Development |
Corporate-sponsored trial |
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors (J5A-OX-JZWA) |
Department of Early Clinical Development |
Corporate-sponsored trial |
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (AZUR-2) |
Department of Medical Oncology |
Corporate-sponsored trial |
PSMA-DC: An Open-label study comparing lutetium (177Lu) vipivotide tetraxetan (also known as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617) versus observation in PSMA positive OMPC(CAAA617D12302). |
Department of Radiation Oncology and Image-Applied Therapy |
Corporate-sponsored trial |
Study of KTE-X19 in Adult Japanese Subjects with Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (JKART-1) |
Department of Hematology |
Corporate-sponsored trial |
Phase I Study of AK1910 in Healthy Japanese Subjects, Healthy Caucasian Subjects, Patients with Systemic Lupus Erythematosus (Single Dose and Multiple Dose Study) |
Department of Rheumatology and Clinical Immunology |
Investigator-initiated trial |
Investigator-initiated phase 1 trial of antisense oligonucleotide against TUG1 for recurrent glioblastoma (TUG trial) |
Department of Neurosurgery |
Corporate-sponsored trial |
First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants with B-cell Malignancies |
Department of Hematology |
Corporate-sponsored trial |
[M23-385]A Phase 1 study of ABBV-706 alone or in combination in adult subjects with advanced solid tumors. |
Department of Early Clinical Development |
Corporate-sponsored trial |
[M24-427]ABBV-400 in Select Advanced Solid Tumor Indications |
Department of Early Clinical Development |
Corporate-sponsored trial |
[M24-311]Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous(IV)ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab |
Department of Early Clinical Development |
Corporate-sponsored trial |
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) |
Department of Respiratory Medicine |
Corporate-sponsored trial |
[M20-638] A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide(R2)Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma(EPCORE FL-1)( [M20-638] EPCORE FL-1) |
Department of Hematology |
Corporate-sponsored trial |
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2- Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07) |
Department of Breast Surgery |
Corporate-sponsored trial |
AB122 Platform study |
Department of Medical Oncology |
Corporate-sponsored trial |
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers(HERIZON-GEA-01) |
Department of Early Clinical Development |
Corporate-sponsored trial |
A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy(TROPION-Breast03) |
Department of Breast Surgery |
Investigator-initiated trial |
A Phase 1 Study of Lomustine and PCV in Japanese Patients with Glioma(LOMG) |
Department of Neurosurgery |
Investigator-initiated trial |
PRIME Study (PRIME Study) |
Department of Nephrology |
Investigator-initiated trial |
NCCH2101/MK011 trial (Perfume trial) |
Department of Medical Oncology |
Corporate-sponsored trial |
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician’s Choice of Endcrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer(evERA Breast Cancer) |
Department of Breast Surgery |
Corporate-sponsored trial |
Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms |
Department of Hematology |
Investigator-initiated trial |
Phase II Trial to Evaluate the Efficacy and Safety of Combination Therapy with Immune Checkpoint Inhibitors and Photodynamic Therapy |
Department of Medical Oncology |
Investigator-initiated trial |
NCCH2201/MK013 trial (CRYSTAL trial) |
Department of Hematology |
Investigator-initiated trial |
Phase I/II trial for safety and pharmacokinetics of ENDOPIN in healthy adults and patients with pain |
Department of Early Clinical Development |
Corporate-sponsored trial |
EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING IDECABTAGENE VICLEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE (BB2121-EAP-001) |
Department of Hematology |
Corporate-sponsored trial |
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants with Advanced Solid Tumors Receiving Intravenous(IV) ABBV-400 |
Department of Early Clinical Development |
Corporate-sponsored trial |
Lenvatinib + pembrolizumab + chemotherapy compared to pembrolizumab + chemotherapy for the first-line treatment of metastatic esophageal cancer |
Department of Medical Oncology |
Corporate-sponsored trial |
A Japanese Phase 2 study of 177Lu-PSMA-617 in participants with PSMA(+) mCRPC (CAAA617A11201) |
Department of Radiation Oncology and Image-Applied Therapy |
Corporate-sponsored trial |
Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release (JCAR017-EAP-001) |
Department of Hematology |
Investigator-initiated trial |
PENETRATE |
Department of Medical Oncology |
Investigator-initiated trial |
Clinical Trial of Alectinib in Patients with ALK positive rare cancer |
Department of Medical Oncology |